[go: up one dir, main page]

FI3727461T3 - EPHA2:lle spesifisiä bisyklisiä peptidiligandeja - Google Patents

EPHA2:lle spesifisiä bisyklisiä peptidiligandeja

Info

Publication number
FI3727461T3
FI3727461T3 FIEP18829926.7T FI18829926T FI3727461T3 FI 3727461 T3 FI3727461 T3 FI 3727461T3 FI 18829926 T FI18829926 T FI 18829926T FI 3727461 T3 FI3727461 T3 FI 3727461T3
Authority
FI
Finland
Prior art keywords
compound
cancer
pharmaceutical composition
seq
harg
Prior art date
Application number
FIEP18829926.7T
Other languages
English (en)
Inventor
Liuhong Chen
Philip Huxley
Silvia Pavan
Rietschoten Katerine Van
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1721259.8A external-priority patent/GB201721259D0/en
Priority claimed from GBGB1804102.0A external-priority patent/GB201804102D0/en
Priority claimed from GBGB1818603.1A external-priority patent/GB201818603D0/en
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Application granted granted Critical
Publication of FI3727461T3 publication Critical patent/FI3727461T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Claims (10)

PATENTTIVAATIMUKSET
1. Yhdiste, joka yhdiste on BCY6136 tai sen farmaseuttisesti hyväksyttävä suola, jolloin mainitulla yhdisteellä BCY6136 on rakenne: DN Oa N ; NOT Lb aN 02 0E meveom o Y ux SNE AN ON SÅN BOYSOGG vo Hoi o + H AN BDCYS136 HN YO — jolloin BCY6099 on sekvenssin SEQ ID NO: 2 mukainen polypeptidi (B-Ala)-Sari0-A(HArg)D-Ci(HyP)LVNPLCiiLHP(D-Asp)W(HArg)Cii (SEQ ID NO: 2) jolloin Sar on sarkosiini, HArg on homoarginiini ja HyP on hydroksiproliini; jolloin sekvenssin SEQ ID NO: 2 mukainen polypeptidi on syklisoitu Ci:ssä, Cii:ssä ja Cii:ssä 1,1’,1”-(1,3,5-triatsinaani-1,3,5-triyyli)triprop-2-en-1-onilla (TATA).
2. Patenttivaatimuksen 1 mukainen yhdiste, jolloin sekvenssi SEO ID NO: 2 on amidoitu C-terminuksessa.
3. Patenttivaatimuksen 1 tai 2 mukainen yhdiste, jolloin farmaseuttisesti hyväksyttävä suola on valittu vapaasta haposta tai natrium-, kalium-, kalsium- tai ammoniumsuolasta.
4. Farmaseuttinen koostumus, joka käsittää jonkin patenttivaatimuksista 1-3 mukaista yhdistettä yhdessä yhden tai useamman farmaseuttisesti hyväksyttävän apuaineen kanssa.
5. Jonkin patenttivaatimuksista 1-3 mukainen yhdiste tai patenttivaatimuksen 4 mukainen farmaseuttinen koostumus käytettäväksi sellaisen sairauden tai häiriön — ehkäisyyn, tukahduttamiseen tai hoitoon, jolle on ominaista EphAZ2:n likailmentyminen sairaassa kudoksessa.
6. Jonkin patenttivaatimuksista 1-3 mukainen yhdiste tai patenttivaatimuksen 4 mukainen farmaseuttinen koostumus käytettäväksi menetelmässä syövän ehkäisemiseksi, tukahduttamiseksi tai hoitamiseksi.
7. Yhdiste — käytettäväksi tai farmaseuttinen koostumus käytettäväksi patenttivaatimuksen 5 mukaisesti, jolloin sairaus tai häiriö on syöpä.
8. Patenttivaatimuksen 6 tai / mukainen yhdiste tai farmaseuttinen koostumus, jossa syöpä on valittu eturauhassyövän, keuhkosyövän, rintasyövän, mahasyövän, —munasarjasyövän, ruokatorven syövän, multippeli myelooman ja fibrosarkooman joukosta.
9. Yhdiste — käytettäväksi tai farmaseuttinen koostumus käytettäväksi patenttivaatimuksen 8 mukaisesti, jolloin keuhkosyöpä on ei-pienisoluinen keuhkokarsinooma (NSCLC) ja/tai jolloin rintasyöpä on kolmoisnegatiivinen — rintasyöpä
10. — Jonkin patenttivaatimuksista 1-3 mukainen yhdiste tai patenttivaatimuksen 4 mukainen farmaseuttinen koostumus käytettäväksi menetelmässä syövän ehkäisemiseksi, tukahduttamiseksi tai hoitamiseksi sitä tarvitsevalla potilaalla, jolloin mainitulla potilaalla on tunnistettu EphA2:n lisääntynyt kopiomäärän variaatio (CNV).
FIEP18829926.7T 2017-12-19 2018-12-19 EPHA2:lle spesifisiä bisyklisiä peptidiligandeja FI3727461T3 (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1721259.8A GB201721259D0 (en) 2017-12-19 2017-12-19 Bicyclic peptide ligands specific for EphA2
GBGB1804102.0A GB201804102D0 (en) 2018-03-14 2018-03-14 Bicycle peptide ligands specific for EphA2
GBGB1818603.1A GB201818603D0 (en) 2018-11-14 2018-11-14 Bicyclic peptide ligands specific for epha2
PCT/GB2018/053678 WO2019122863A1 (en) 2017-12-19 2018-12-19 Bicyclic peptide ligands specific for epha2

Publications (1)

Publication Number Publication Date
FI3727461T3 true FI3727461T3 (fi) 2025-08-15

Family

ID=64902125

Family Applications (2)

Application Number Title Priority Date Filing Date
FIEP22161978.6T FI4053145T3 (fi) 2017-12-19 2018-12-19 EphA2:lle spesifisiä peptidiligandeja
FIEP18829926.7T FI3727461T3 (fi) 2017-12-19 2018-12-19 EPHA2:lle spesifisiä bisyklisiä peptidiligandeja

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FIEP22161978.6T FI4053145T3 (fi) 2017-12-19 2018-12-19 EphA2:lle spesifisiä peptidiligandeja

Country Status (27)

Country Link
US (5) US11484602B2 (fi)
EP (4) EP3727460B1 (fi)
JP (4) JP7293231B2 (fi)
KR (2) KR102791088B1 (fi)
CN (4) CN111741771B (fi)
AU (3) AU2018387417C9 (fi)
BR (2) BR112020012349A2 (fi)
CA (2) CA3085253A1 (fi)
CY (1) CY1125367T1 (fi)
DK (3) DK4053145T3 (fi)
ES (3) ES2922632T3 (fi)
FI (2) FI4053145T3 (fi)
HR (2) HRP20220871T1 (fi)
HU (1) HUE059126T2 (fi)
IL (3) IL321490A (fi)
LT (2) LT3727460T (fi)
MX (2) MX2020006474A (fi)
PH (1) PH12020550929A1 (fi)
PL (3) PL3727461T3 (fi)
PT (3) PT4053145T (fi)
RS (1) RS67248B1 (fi)
SA (1) SA520412268B1 (fi)
SG (2) SG11202005494QA (fi)
SI (2) SI3727461T1 (fi)
SM (1) SMT202500312T1 (fi)
TW (1) TWI825046B (fi)
WO (2) WO2019122860A1 (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
KR20200139236A (ko) 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
JP2022528887A (ja) * 2019-04-02 2022-06-16 バイスクルテクス・リミテッド バイシクルトキシンコンジュゲートおよびその使用
CN113811541A (zh) 2019-05-09 2021-12-17 拜斯科技术开发有限公司 Ox40特异性的双环肽配体
TWI862640B (zh) * 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP2022544246A (ja) * 2019-08-13 2022-10-17 バイスクルテクス・リミテッド 修飾された多量体二環式ペプチドリガンド
PL4464721T3 (pl) * 2019-10-03 2025-08-25 Bicycletx Limited Heterotandemowe kompleksy peptydów bicyklicznych
IL293200A (en) * 2019-11-27 2022-07-01 Bicycletx Ltd Bicyclic peptide ligands specific for epha2 and uses thereof
IL298382A (en) * 2020-05-20 2023-01-01 Bicycletx Ltd Nectin-4-specific bicyclic peptide ligands and their uses
IL298868A (en) 2020-06-12 2023-02-01 Bicycletx Ltd Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
US20220031858A1 (en) * 2020-08-03 2022-02-03 Bicycle TX Limited Novel linkers
US20240197897A1 (en) 2021-01-08 2024-06-20 Bicycle TX Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
EP4349857A4 (en) 2021-05-25 2025-06-11 Vaxcell-Bio Monobody-based chimeric antigen receptor and immune cell including same
US20250121076A1 (en) * 2021-08-17 2025-04-17 Medshine Discovery Inc. Polypeptide drug conjugate having novel structure and application thereof
JP2024537396A (ja) * 2021-10-14 2024-10-10 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド ＥｐｈＡ２の二環式ペプチドリガンド及びそのコンジュゲート
KR20230140746A (ko) * 2022-03-30 2023-10-10 연세대학교 산학협력단 암전이의 검출용 신규 바이오마커
CN116063379B (zh) * 2022-08-23 2025-05-02 中国药科大学 EphA2靶向多肽及其应用
CN120835795A (zh) 2023-03-09 2025-10-24 拜斯科技术开发有限公司 双环毒素偶联物及其中间体的合成
WO2024261490A1 (en) 2023-06-23 2024-12-26 Bicycletx Limited Bicyclic peptide ligands specific for nk cells
WO2025191096A1 (en) * 2024-03-14 2025-09-18 Bicycletx Limited Bicyclic peptide
CN119874840B (zh) * 2025-03-31 2025-08-08 晶核生物医药科技(上海)有限公司 一种双环肽及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US20020164788A1 (en) 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
DE69938353T2 (de) 1998-09-24 2009-03-05 Indiana University Research and Technology Corp., Indianapolis Wasserlösliche lumineszente quantum-dots sowie deren biokonjugate
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
CZ303875B6 (cs) 1999-12-10 2013-06-05 Pfizer Products Inc. Pyrrolo[2,3-d]pyrimidinová sloucenina a farmaceutická kompozice s jejím obsahem
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
CA2477163C (en) 2002-02-21 2010-07-27 Institute Of Virology Soluble form of carbonic anhydrase ix (s-ca-ix), assays to detect s-ca ix, and ca ix's coexpression with her-2/neu/c-erbb-2, and ca ix-specific monoclonal antibodies to non-immunodominant epitopes
CN1674929B (zh) 2002-08-14 2013-07-17 赛伦斯治疗公司 蛋白激酶Nβ的应用
EP1852441B1 (en) * 2002-09-24 2012-03-28 The Burnham Institute Agents that modulate EPH receptor activity
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
EP2371835A1 (en) 2003-07-03 2011-10-05 The Trustees Of The University Of Pennsylvania Inhibition of syk kinase expression
JP2008504013A (ja) 2004-02-06 2008-02-14 モルフォシス・アクチェンゲゼルシャフト 抗ｃｄ３８ヒト抗体及びその用途
US7151047B2 (en) 2004-04-28 2006-12-19 Warren Chan Stable, water-soluble quantum dot, method of preparation and conjugates thereof
WO2005113556A1 (en) 2004-05-13 2005-12-01 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
US7449458B2 (en) 2005-01-19 2008-11-11 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
SI1844337T1 (sl) 2005-01-24 2013-11-29 Pepscan Systems B.V. Povezovalne spojine, imunogene spojine in peptidomimetiki
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
WO2007044729A2 (en) 2005-10-07 2007-04-19 Exelixis, Inc. N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
MY167260A (en) 2005-11-01 2018-08-14 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
KR101391900B1 (ko) 2005-12-13 2014-05-02 인사이트 코포레이션 야누스 키나아제 억제제로서의 헤테로아릴 치환된 피롤로［2,3-ｂ］피리딘 및 피롤로［2,3-ｂ］피리미딘
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
UA95799C2 (en) 2006-04-26 2011-09-12 Ф. Хоффманн-Ля Рош Аг Pharmaceutical compounds
CN101622276B (zh) * 2006-07-18 2015-04-22 赛诺菲-安万特 用于治疗癌症的抗epha2的拮抗抗体
WO2008033561A2 (en) 2006-09-15 2008-03-20 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP2010530437A (ja) 2007-06-18 2010-09-09 メディミューン，エルエルシー ＥｐｈＡ２およびＥｒｂＢ２を発現する細胞の相乗的治療
US8680022B2 (en) 2008-02-05 2014-03-25 Bicycle Therapeutics Limited Methods and compositions
MX2010010012A (es) 2008-03-11 2010-10-20 Incyte Corp Derivados de azetidina y ciclobutano como inhibidores de jak.
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
GB201117428D0 (en) 2011-10-07 2011-11-23 Bicycle Therapeutics Ltd Structured polypeptides with sarcosine linkers
PL2764140T3 (pl) 2011-10-07 2018-04-30 Bicyclerd Limited Modulacja specyficzności polipeptydów ustrukturyzowanych
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
US20140274759A1 (en) 2013-03-15 2014-09-18 Bicycle Therapeutics Limited Modification of polypeptides
GB201306623D0 (en) 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
WO2014190257A2 (en) 2013-05-23 2014-11-27 Ohio State Innovation Foundation Chemical synthesis and screening of bicyclic peptide libraries
SG11201602889TA (en) 2013-10-28 2016-05-30 Bicycle Therapeutics Ltd Novel polypeptides
JP6875129B2 (ja) 2014-05-08 2021-05-19 ノボダイアックス， インコーポレイテッド 直接的な免疫組織化学アッセイ
PL3149025T3 (pl) 2014-05-21 2019-11-29 Entrada Therapeutics Inc Peptydy penetrujące komórkę i sposoby ich wytwarzania i stosowania
US10532106B2 (en) 2014-10-29 2020-01-14 Bicyclerd Limited Bicyclic peptide ligands specific for MT1-MMP
WO2016171242A1 (ja) 2015-04-24 2016-10-27 第一三共株式会社 Ｅｐｈａ２の検出
AU2016256226A1 (en) * 2015-04-28 2017-11-23 Ecole polytechnique fédérale de Lausanne (EPFL) Novel inhibitors of the enzyme activated factor XII (FXIIa)
CN108883199A (zh) 2016-03-16 2018-11-23 梅里麦克制药股份有限公司 肝配蛋白受体a2(epha2)的纳米脂质体靶向和相关诊断
MA45328A (fr) 2016-04-01 2019-02-06 Avidity Biosciences Llc Compositions acide nucléique-polypeptide et utilisations de celles-ci
KR102426765B1 (ko) 2016-04-22 2022-07-29 엘리게이터 바이오사이언스 에이비 Cd137에 대한 신규한 이중특이성 폴리펩타이드
GB201607827D0 (en) 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
WO2018096365A1 (en) 2016-11-27 2018-05-31 Bicyclerd Limited Methods for treating cancer
JP2020502238A (ja) 2016-12-23 2020-01-23 バイスクルアールディー・リミテッド 新規連結構造を有するペプチド誘導体
JP7387440B2 (ja) 2016-12-23 2023-11-28 バイスクルテクス・リミテッド Ｍｔ１－ｍｍｐに結合するためのペプチドリガンド
US10624968B2 (en) 2017-01-06 2020-04-21 Bicyclerd Limited Compounds for treating cancer
EP3585431A4 (en) 2017-02-24 2020-12-16 MacroGenics, Inc. BISPECIFIC BINDING MOLECULES CAPABLE OF BINDING TO CD137 AND TUMOR ANTIGENS, AND THEIR USES
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
US10857196B2 (en) 2017-04-27 2020-12-08 Bicycletx Limited Bicyclic peptide ligands and uses thereof
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
CN111183147B (zh) 2017-08-04 2024-07-05 拜斯科技术开发有限公司 Cd137特异性的双环肽配体
WO2019034868A1 (en) 2017-08-14 2019-02-21 Bicyclerd Limited CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF
US20200291096A1 (en) 2017-08-14 2020-09-17 Bicyclerd Limited Bicyclic peptide ligand sting conjugates and uses thereof
US11410028B2 (en) 2017-09-20 2022-08-09 Look Dynamics, Inc. Photonic neural network system
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
WO2019136442A1 (en) 2018-01-08 2019-07-11 Kleo Pharmaceuticals, Inc. Cd16a binding agents and uses thereof
JP2021514953A (ja) 2018-02-23 2021-06-17 バイスクルテクス・リミテッド 多量体二環式ペプチドリガンド
KR20200139236A (ko) 2018-04-04 2020-12-11 바이사이클티엑스 리미티드 헤테로탠덤 비사이클릭 펩티드 복합체
AU2019272575A1 (en) 2018-05-21 2020-12-10 Compass Therapeutics Llc Compositions and methods for enhancing the killing of target cells by NK cells
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
US10919937B2 (en) 2018-10-23 2021-02-16 Bicycletx Limited Bicyclic peptide ligands and uses thereof
BR112021011340A2 (pt) 2018-12-13 2021-09-08 Bicycletx Limited Ligantes de peptídeo bicíclico específicos para mt1-mmp
AU2019402097A1 (en) 2018-12-17 2021-06-10 Revitope Limited Twin immune cell engager
WO2020128526A1 (en) 2018-12-21 2020-06-25 Bicycletx Limited Bicyclic peptide ligands specific for pd-l1
JP2022528887A (ja) 2019-04-02 2022-06-16 バイスクルテクス・リミテッド バイシクルトキシンコンジュゲートおよびその使用
CN113811541A (zh) 2019-05-09 2021-12-17 拜斯科技术开发有限公司 Ox40特异性的双环肽配体
TWI862640B (zh) 2019-07-30 2024-11-21 英商拜西可泰克斯有限公司 異質雙環肽複合物
JP2022544246A (ja) 2019-08-13 2022-10-17 バイスクルテクス・リミテッド 修飾された多量体二環式ペプチドリガンド
PL4464721T3 (pl) 2019-10-03 2025-08-25 Bicycletx Limited Heterotandemowe kompleksy peptydów bicyklicznych
IL293200A (en) 2019-11-27 2022-07-01 Bicycletx Ltd Bicyclic peptide ligands specific for epha2 and uses thereof
IL298868A (en) 2020-06-12 2023-02-01 Bicycletx Ltd Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
KR20230074721A (ko) 2020-08-17 2023-05-31 바이사이클티엑스 리미티드 Nectin-4에 특이적인 이환 콘쥬게이트 및 이의 용도
US20240197897A1 (en) 2021-01-08 2024-06-20 Bicycle TX Limited Heterotandem bicyclic peptide complexes
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer

Also Published As

Publication number Publication date
JP2021506936A (ja) 2021-02-22
SA520412268B1 (ar) 2023-11-12
JP7404241B2 (ja) 2023-12-25
BR112020012349A2 (pt) 2020-11-24
HUE059126T2 (hu) 2022-10-28
SMT202500312T1 (it) 2025-09-12
CY1125367T1 (el) 2025-05-09
DK3727460T3 (da) 2022-07-11
ES3037964T3 (en) 2025-10-08
CN111787955A (zh) 2020-10-16
FI4053145T3 (fi) 2024-09-09
IL321490A (en) 2025-08-01
DK4053145T3 (da) 2024-09-09
US20240000957A1 (en) 2024-01-04
MX2020006474A (es) 2020-12-11
CN111787955B (zh) 2024-06-04
LT3727460T (lt) 2022-07-25
SG11202005494QA (en) 2020-07-29
AU2018387417C1 (en) 2024-08-15
EP4053145B1 (en) 2024-06-12
AU2018387418B2 (en) 2024-01-25
SI3727460T1 (sl) 2022-11-30
IL275440A (en) 2020-08-31
BR112020012246A2 (pt) 2020-11-24
WO2019122863A1 (en) 2019-06-27
CN118598945A (zh) 2024-09-06
PT3727461T (pt) 2025-08-29
SG11202005495UA (en) 2020-07-29
PL4053145T3 (pl) 2024-11-25
HRP20220871T1 (hr) 2022-12-23
TW201927306A (zh) 2019-07-16
JP7503689B2 (ja) 2024-06-20
CN118909043A (zh) 2024-11-08
AU2018387417C9 (en) 2024-09-12
EP4582436A3 (en) 2025-10-08
IL275437B1 (en) 2025-07-01
AU2018387417A1 (en) 2020-07-30
US20220289792A1 (en) 2022-09-15
HRP20251070T1 (hr) 2025-11-07
DK3727461T3 (da) 2025-08-18
AU2018387418A1 (en) 2020-07-30
SI3727461T1 (sl) 2025-11-28
TWI825046B (zh) 2023-12-11
US11696956B2 (en) 2023-07-11
CA3086257A1 (en) 2019-06-27
WO2019122860A1 (en) 2019-06-27
IL275440B1 (en) 2023-11-01
US20190184025A1 (en) 2019-06-20
PT4053145T (pt) 2024-09-10
IL275437A (en) 2020-08-31
IL275437B2 (en) 2025-11-01
PT3727460T (pt) 2022-07-14
JP2023130345A (ja) 2023-09-20
ES2922632T3 (es) 2022-09-19
EP4582436A2 (en) 2025-07-09
CN111741771B (zh) 2024-08-06
CA3085253A1 (en) 2019-06-27
JP7293231B2 (ja) 2023-06-19
MX2020006482A (es) 2020-12-10
JP2024138253A (ja) 2024-10-08
IL275440B2 (en) 2024-03-01
JP2021506910A (ja) 2021-02-22
KR102791088B1 (ko) 2025-04-08
EP3727460A1 (en) 2020-10-28
EP3727461B1 (en) 2025-07-09
AU2018387417B2 (en) 2023-11-23
PL3727460T3 (pl) 2022-08-22
US11833211B2 (en) 2023-12-05
PL3727461T3 (pl) 2025-10-27
US11484602B2 (en) 2022-11-01
EP3727461A1 (en) 2020-10-28
US20240189436A1 (en) 2024-06-13
LT3727461T (lt) 2025-09-25
RS67248B1 (sr) 2025-10-31
AU2024202618A1 (en) 2024-06-13
CN111741771A (zh) 2020-10-02
KR102890185B1 (ko) 2025-11-24
KR20200105839A (ko) 2020-09-09
KR20200105840A (ko) 2020-09-09
ES2987839T3 (es) 2024-11-18
US20230144799A1 (en) 2023-05-11
EP3727460B1 (en) 2022-04-13
EP4053145A1 (en) 2022-09-07
PH12020550929A1 (en) 2021-05-17

Similar Documents

Publication Publication Date Title
FI3727461T3 (fi) EPHA2:lle spesifisiä bisyklisiä peptidiligandeja
JP2025122030A5 (fi)
FI3849534T3 (fi) Yhdistelmähoidot
IL292193B1 (en) Anti-b7-h1 antibodies for treating tumors
RU2012137503A (ru) Лекарственный препарат для лечения и/или профилактики рака
JPWO2021019245A5 (fi)
JP2019527706A5 (fi)
RU2019106663A (ru) Комбинированная терапия рака
JOP20210319A1 (ar) مركبات بيروليدين
JP2014169326A5 (fi)
ES2733129T3 (es) Un nonapéptido con actividad antitumoral
EA201791727A1 (ru) 7-бензил-4-(2-метилбензил)-2,4,6,7,8,9-гексагидроимидазо[1,2-а]пиридо[3,4-е]пиримидин-5(1н)-он, его аналоги и соли и способы их применения в терапии
RU2012137504A (ru) Фармацевтическая композиция для лечения и/или профилактики рака
JP2020521797A5 (fi)
PH12020551118A1 (en) Modified lipidated relaxin b chain peptides and their therapeutic use
MX2022001863A (es) Metodos para tratar los tumores del estroma gastrointestinal.
HRP20160045T1 (hr) Metoda lijeäśenja raka pomoä†u antagonista dll4 i kemoterapijskog sredstva
IL240695B1 (en) Nme inhibitors and methods of using nme inhibitors
MX2023013715A (es) Regímenes de dosis de ecubectedina.
WO2015117127A1 (en) Galectin-3 inhibitor (gal-3m) is associated with additive anti-myeloma and anti-solid tumor effects, decreased osteoclastogenesis and organ protection when used in combination with proteasome inhibitors
MX390044B (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia.
RU2012108179A (ru) Новый пептид и его применение
RU2018107930A (ru) Агонисты tlr4, их композиции и применение для лечения рака
RU2017105817A (ru) Комбинированная терапия
CA3098189C (en) N-PHENYL-N'-(4-{[6-(1H-IMIDAZOL-1YL)-4-PYRIMIDINYL]AMINO}PHENYL) UREA DERIVATIVES USED AS MCT4 INHIBITORS FOR CANCER TREATMENT